Biobank aims to unlock secrets of phage therapy against superbugs
NCT ID NCT05314426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study creates a biobank of blood and fluid samples from up to 100 people who have received or will receive phage therapy for antibiotic-resistant bacterial infections. Researchers will review medical records and collect biospecimens to better understand how phage therapy works. The goal is to support future research and improve treatment options for hard-to-treat infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could help researchers understand how phage therapy works against antibiotic-resistant infections.
- What could go wrong
- This is an observational biobank study, not a treatment trial. It collects information but does not test whether phage therapy itself is effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIOPHAGE THERAPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.